

SPECIALTY GUIDELINE MANAGEMENT

MENOPUR (menotropins for injection)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Menopur is indicated for development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology (ART) cycle.

All other indications are considered experimental/investigational and not medically necessary.

II. MEDICAL BENEFIT ALIGNMENT

Specialty Guideline Management coverage review will be bypassed for drug(s) being requested for a procedure that has been approved under a member's medical benefit plan. Such members will be exempt from the requirements in Sections III. A medical authorization number and confirmation of the approved procedure(s) will be required.

NOTE: Some plans may opt-out of medical benefit alignment. Members receiving coverage under such plans must meet the requirements in Sections III.

III. CRITERIA FOR INITIAL APPROVAL

Follicle stimulation

Authorization of 12 months may be granted for members undergoing ovulation induction or assisted reproductive technology (ART) who meet any of the following criteria:

- A. Member has completed three or more previous cycles of clomiphene or letrozole.
- B. Member has a risk factor for poor ovarian response to clomiphene or letrozole.
- C. Member has a contraindication or exclusion to clomiphene or letrozole.
- D. Member is 37 years of age or older.

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. REFERENCES

1. Menopur [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; December 2021.
2. Practice Committee of the American Society for Reproductive Medicine. Evidence-based treatments for couples with unexplained infertility: a guideline. *Fertil & Steril.* 2020; 113(2):305-322.

Reference number(s)
1991-A, 1992-A